Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Pfizer Approvals Don’t Quit: Chantix Clears FDA For Smoking Cessation

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Advantage of varenicline over GSK’s Zyban is more pronounced over the short-term than long-term.

You may also be interested in...



NICE Recommends Cost Effectiveness Of Pfizer’s Smoking Cessation Drug

Varenicline is superior to nicotine replacement therapy and bupropion in achieving continuous abstinence, NICE determines.

NICE Recommends Cost Effectiveness Of Pfizer’s Smoking Cessation Drug

Varenicline is superior to nicotine replacement therapy and bupropion in achieving continuous abstinence, NICE determines.

Two Nicotine Addiction Vaccines On Phase III Racetrack

Novartis partners with Cytos on CYT002-NicQb, while Nabi looks to partner NicVax prior to pivotal trials in second half.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS064133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By